Teva Pharma (TEVA) PT Lowered to $21 at Barclays; Generic Copaxone 40mg Approval 'Will Offset Some Contracting Strategies... Hurt Sentiment'
Tweet Send to a Friend
Barclays lowered its price target on Teva Pharma (NYSE: TEVA) to $21.00 (from $23.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
